Despite numerous large studies over the past decade for patients with unresectable hepatocellular carcinoma (HCC), a second-line standard of care remained largely elusive following standard frontline therapy with sorafenib (Nexavar)—that is until findings from the phase III RESORCE trial exploring regorafenib (Stivarga) were reported earlier this year.
The phase III RESORCE trial, which was initially presented at the 2016 World Congress on Gastrointestinal Cancer, showed that regorafenib improved overall survival (OS) by 2.8 months compared with placebo as a second-line therapy for patients with HCC. Median OS was 10.6 months with regorafenib versus 7.8 months for placebo (HR, 0.62; 95% CI, 0.50-0.78; P <.001).

Read the full article

View more articles from the 10th ILCA Annual Conference